Aditxt Inc. Subsidiary Pearsanta Invited to Submit Full Proposal for DoD-Funded Ovarian Cancer Diagnostic Study

Aditxt Inc. (NASDAQ: ADTX) has announced that its subsidiary, Pearsanta, Inc., has received an invitation to submit a full proposal for the U.S. Department of Defense's OCRP Pilot Award. This opportunity underscores the potential of Pearsanta's Mitomic(R) Ovarian Test (MOT(TM)), a pioneering blood-based diagnostic designed for the early detection of ovarian cancer. The pre-proposal by Pearsanta was met with positive reviews for its scientific merit and innovation, paving the way for this next step. A successful grant application could secure up to $350,000 over two years, funding a multi-center clinical study to validate the test and prepare for its commercial launch as a laboratory-developed test.

The significance of this development lies in the potential of the Mitomic Ovarian Test to revolutionize the early detection of ovarian cancer, a disease often diagnosed at advanced stages due to the lack of early symptoms. Early detection is crucial for improving survival rates, making Pearsanta's research a critical endeavor in the fight against ovarian cancer. For more details on the press release, visit https://ibn.fm/lep5n.